company background image
ACIU logo

AC Immune NasdaqGM:ACIU Stock Report

Last Price

US$1.74

Market Cap

US$169.2m

7D

6.7%

1Y

-44.9%

Updated

19 May, 2025

Data

Company Financials +

AC Immune SA

NasdaqGM:ACIU Stock Report

Market Cap: US$169.2m

ACIU Stock Overview

A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. More details

ACIU fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 97.1% below our estimate of its fair value

Revenue is forecast to grow 43.41% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

AC Immune SA Competitors

Price History & Performance

Summary of share price highs, lows and changes for AC Immune
Historical stock prices
Current Share PriceUS$1.74
52 Week HighUS$4.98
52 Week LowUS$1.43
Beta1.62
1 Month Change17.57%
3 Month Change-34.09%
1 Year Change-44.94%
3 Year Change-48.37%
5 Year Change-76.64%
Change since IPO-88.89%

Recent News & Updates

Benign Growth For AC Immune SA (NASDAQ:ACIU) Underpins Stock's 26% Plummet

Apr 01
Benign Growth For AC Immune SA (NASDAQ:ACIU) Underpins Stock's 26% Plummet

AC Immune: Leader In Dementia Therapies, A Space Littered With Failures

Feb 19

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

Jul 26

Recent updates

Benign Growth For AC Immune SA (NASDAQ:ACIU) Underpins Stock's 26% Plummet

Apr 01
Benign Growth For AC Immune SA (NASDAQ:ACIU) Underpins Stock's 26% Plummet

AC Immune: Leader In Dementia Therapies, A Space Littered With Failures

Feb 19

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

Jul 26

AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Jun 15
AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

Jun 15
Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

May 24
AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Apr 05
AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Mar 15
We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth

Oct 06
Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Jun 03
We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

Nov 25
Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

AC Immune Non-GAAP EPS of -$0.23 in-line

Jul 28

Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

Jul 06
Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Feb 03
AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

May 09
Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

Feb 28
How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts

Jan 24
Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts

We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely

Jan 19
We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely

If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%

Dec 15
If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%

Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues

Nov 19
Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues

Shareholder Returns

ACIUUS BiotechsUS Market
7D6.7%0.8%1.6%
1Y-44.9%-13.8%11.7%

Return vs Industry: ACIU underperformed the US Biotechs industry which returned -14.7% over the past year.

Return vs Market: ACIU underperformed the US Market which returned 11.9% over the past year.

Price Volatility

Is ACIU's price volatile compared to industry and market?
ACIU volatility
ACIU Average Weekly Movement7.5%
Biotechs Industry Average Movement12.0%
Market Average Movement8.1%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market4.1%

Stable Share Price: ACIU has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ACIU's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003153Andrea Pfeiferwww.acimmune.com

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company’s SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer’s disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD.

AC Immune SA Fundamentals Summary

How do AC Immune's earnings and revenue compare to its market cap?
ACIU fundamental statistics
Market capUS$169.19m
Earnings (TTM)-US$62.42m
Revenue (TTM)US$33.92m
5.1x
P/S Ratio
-2.8x
P/E Ratio

Is ACIU overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACIU income statement (TTM)
RevenueCHF 28.30m
Cost of RevenueCHF 63.32m
Gross Profit-CHF 35.02m
Other ExpensesCHF 17.06m
Earnings-CHF 52.08m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.53
Gross Margin-123.76%
Net Profit Margin-184.05%
Debt/Equity Ratio0%

How did ACIU perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/19 10:11
End of Day Share Price 2025/05/19 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AC Immune SA is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas ShraderBTIG
Alethia YoungCredit Suisse
Andrew FeinH.C. Wainwright & Co.